Disposition of Comments
Project ID: GEND0508
The Agency for Healthcare Research and Quality's (AHRQ) Technology
Assessment (TA) Program supports and is committed to the transparency of its review process. Therefore, invited peer review comments and public review comments are publicly posted on the TA Program Web site at http://www.ahrq.gov/clinic/techix.htm within 3 months after the associated final report is posted on this Web site.
This document presents the peer review comments and public review comments
sent in response to the draft report, Update of Horizon Scans of Genetic Tests Currently Available for Clinical Use in Cancers, posted on the AHRQ Web site from December 22, 2010, through January 10, 2011. The final version of the report is available
online.
Select for printable
version (PDF
file, 1.6 MB). Plugin Software Help.
Contents
Select for Table
1: Invited Peer Reviewer Comments.
Select for Table
2: Public Review Comments
Table
1: Invited Peer Reviewer Comments
Reviewer1 |
Section2 |
Reviewer Comments |
Author Response3 |
1 |
General |
This update can be a valued addition to contributing to current knowledge
about the availability of genetic tests for cancer. In reviewing, there
were several issues raised that should be addressed. |
Thank you. |
1 |
Introduction/
Background |
Page 8: it is stated that a main objective is to provide a preliminary estimate
on the amount of published literature available on each genetic test. It
should be noted that literature covers a broad range of topics associated with
a particular test ranging from research studies not having clinical applications
to those that do. |
This is stated on the page 11 under exploratory PubMed search. |
1 |
Methods |
Page 10. Are predictive tests excluded? If not you may wish
to include this as a category at the top of this page. Understandably,
it is less applicable to the Medicare population although detecting disease
recurrence is a form of predictive testing.
Page 10. Under inclusion criteria for tests offered by Internet sites
requiring a physician order, I would add the caveat to include those performed
in a laboratory certified under the CLIA regulations. This gets into
the DTC realm which as you know is tricky.
Page 10. With regard to your exclusion criteria, do you want to say
tests for conditions that exclusively result in death before reaching adulthood? This
is difficult because some conditions occur, as a consequence of the genetics,
before and after adulthood. Perhaps it is better to address this in
the inclusion criteria as tests for conditions that manifest within the Medicare
population.
Page 11. It is not clear how the categories are reflected in the tables
presented later in this report. There does not appear to be "category" entry. Possibly
the "Purpose" entry?
Page 12. I would not completely discount the published literature
but would say that it has significant limitations for some of the reasons
mentioned. I would delete the first reason—search strategies can be
devised, I would probably delete the second—this is a limitation of your
effort and not the concept, your 5th reason seems irrelevant since you will
not be addressing the publication of associations; only tests. Another
reason is the peer-reviewed literature is simply not the primary forum for
providing information about new tests. This should be mentioned.
Page 12. It is questionable whether GeneReviews is grey literature
since entries are peer reviewed; albeit by a somewhat different that a journal
but with similarities.
Page 13—The international laboratory is not as broad-based as implied. It
fundamentally focuses upon molecular testing with fewer entries for cytogenetic
and biochemical genetic testing.
Comment—Did you look at the Association for Molecular Pathology test directory
(www.amp.org) that specifically deals with cancer testing (at least a part
of the directory)?
Page 15—Under clinical use—It seems that the only clinical use this
report is addressing is "clinical" use. This would be consistent
with the title of this report. Otherwise, the title may need to be
change as well as the stated focus for this effort.
Page 16—Instead of 9) Marker—why not be more direct and call this entry "Medline
search parameters"?
Page 16—With regard to the "Organ" entry—Do you wish to differentiate
between primary site and metastases? For example, renal cell carcinoma
begins in the organ but metastasizes to multiple other organs. If you
wish to list all possible organ sites, you should differentiate primary from
others. |
Page 10: We will add the term predictive tests as these are not excluded
from the database.
Page 10. Any genetic tests that require a physician order are of interest to
the report.
Page 10. We have reworded the exclusion criteria.
Page 11. We have edited the categories so that they are fairly matched with
those listed in the table
Page 12: Only the tests are obtained through grey literature searching,
sometimes may include review of selected narrative reviews. The description
of the test and its clinical application does include a variety of sources
including peer reviewed literature.
Page 13: This statement directly reflects what was posted on the Web site.
The last line in our introduction clarifies this.
Thank you for directing us to the Web site, we will include any tests that
are not currently listed in our database, but are available at the amp.org
Web site. Our inclusion criteria are similar to that listed in the 2006 report
to focus on the most common cancers.
Page 15. Thank you.
Page 16. We have clarified this.
Page 16. The suggested search strategy is more applicable for focused systematic
reviews. |
1 |
Results |
Page 19—last sentence—It is unclear how the graphics plot may be used
for identifying tests for future focused reviews. |
At the suggestion of many reviewers the graphic plots have been omitted out. |
1 |
Discussion/ Conclusion |
Page 23—I would be hesitant to state that "in this report along
with genetic tests identified in our 2006 report are fairly comprehensive" without
the caveat that other tests are available that would not be expected to be
described within the sources interrogated. For example, it is common
for academic medical center laboratories to develop/offer some tests at the
request of their physicians. These tests would not typically be offered
or marketed beyond the academic center in which they are offered and if not
for a heritable condition, would less likely be considered for entry into
the GeneTests database.
Page 24—In stating, "we have selected those that are available for
clinical applications in screening, diagnosis, prognosis, disease management,
or patient monitoring......." Should "prediction" and/or "disease
recurrence" be included or is this covered. It is not clear where
this is included within these categories although it is mentioned earlier
in the manuscript. I am ok with inclusion in one of these categories
but should be expressively stated earlier in the manuscript. |
Page 23. Thank you for pointing this; we have added a statement to clarify
the same.
Page 24. We have added the suggested terms in the discussion. |
1 |
Tables |
Consistent fields for "availability" are not used. This
needs to be considered. For instance, in some cases, a generic heading
such as "commercial laboratory" is provided and in other cases,
a specific company is cited. Also, you include both manufacturers
(e.g., Roche), and reference to performing laboratories.
With regards to "tests in development" (e.g., Roche Amplichip
for breast cancer)—do you wish to include these selectively because there
are probably hundreds of which only a few will make it to clinical use.
It may be useful to have somewhat of an expanded discussion about the graphs
provided under each entry. I would speculate that references cited
address both basic and clinical research findings. If this is not true
and references are specific to the application of the test in clinical use,
this should be stated. If this level of specificity is not possible,
this limitation should be described.
You include a number of immunohistochemical and immunostaining tests in
your table. It should be stated in the text that for purposes of this
report, you are considering these genetic tests because specific analytes
are targeted. This is important because some professionals would not
consider such tests as "genetic". For example, the Hybridtech
free PSA test for prostate cancer would not be considered a genetic test
by some professionals. Similarly, the NMP22® test kit which is a
quantitative assay would be on the fringes for what might be considered a
genetic test. Most would probably consider this more a quantitative
immunochemical than a genetic test.
When designating the purpose as "pharmacogenetic", it would be
helpful to further classify according to one of your criteria—screening,
diagnosis, prognosis, disease management, or patient monitoring.
In some instances, you mention county/region specific availability—this
should be consistently presented throughout all entries.
Wtih regards to LBA®AFP-L3 testing, the purpose is a different category
not previously described—arguing again for the need to use consistent descriptors.
It is important to strongly emphasize that the description is pulled from
an external source. For instance, in stating that "MammaPrint" uses
the latest in molecular technology should not be interpreted as an AHRQ conclusion.
With regards to MGMT methylation testing, this raises the need to state
that you are also including epigenetic testing in your review. This
can be stated in the main text. The term will need to be defined.
With regards to Oncotype DX, you note that this test has limited availability. "limited" can
have several meanings and in the context of other tests described, this might
not be the only one. I would not say "limited". |
Thank you we have removed this test as it is still in development. All
included tests have fully been developed and are available for clinical use.
Yes, we have clarified the nature of preliminary searches conducted during
horizon scanning.
We have clarified in our text that the graphs accompanying each one page
are from preliminary searches and can address both basic and clinical research
findings. However, the searches are limited to studies conducted in human. Our
report used a broad definition of genetic tests put forth by the 2008 SACGHS
report and it is possible that the tests included under this definition may
not be defined as "genetic test" by other professional groups.
We have changed pharmacogenetic to therapeutic management consistent with
our categories.
Thank you, we have made an effort to make our descriptors consistent.
Thank you we have made edits. |
2 |
General |
Moreover, the report was excellent. The
draft could benefit from a final, careful proofreading for a few minor
grammatical issues but overall it looks very good. I would have liked
to see more information on the database that is mentioned in the report.
Specifically, are there plans to make the GeneTestTracker publically available,
and if so, will it be freely accessible? Can anything be said about differences
between the database and the planned Genetic Testing Registry from NIH? |
We have shared our database with those at
NIH who are involved in Genetic Testing Registry, since some of the fields
are similar. Currently, we are not aware of any plans to make the GeneTestTracker
publically available. |
2 |
Introduction/
Background |
This section was brief but generally adequate.
I appreciated the contrasting between cancer vs. non-cancer tests by the
relatively larger number of tests for somatic mutations in the former,
however, it made me wonder if this is the major reason why scanning and
reports are divided along cancer/non-cancer lines? If so, this should
be clearly stated. If additional contrasts can be made, this might
be helpful as well. I also wondered whether anything can be said
about the absolute number of different genetic tests currently available
for cancer vs. non-cancer disorders |
Based on our original reports and further
work assignments, the reports are published alternate years. The tests
are selected based on their applicability to the elderly population and
hence do not reflect the absolute number of different genetic tests currently
available for cancer vs. non-cancer disorders for all age groups. |
2 |
Methods |
Table 1 is very helpful, but it made me wonder
about the details on how the selection of labs was made. It might be
good to explain why none of the academic laboratories (e.g., Emory University
School of Medicine and Baylor College of Medicine) that offer molecular genetic
testing for a large number diseases are included in the search. Also
it appears that the laboratories that offer molecular genetic tests for the
highest numbers of diseases (according to GeneTests data: ftp://ftp.ncbi.nih.gov/pub/GeneTests/reports/IX/IXB1_report.txt)
were not included and it may be a good idea to address this in the report. This
may be as simple as the fact that some only offer tests for rare, Mendelian
disorders, or that an international lab may not offer services in the U.S. I
was not sure, but felt additional information here would be helpful to readers. |
We do search major academic searches and specifically,
Baylor College of Medicine has been listed in one of our previous reports.
Listed laboratories in this report are the ones that we have had some recent
success in identifying genetic tests. We are unable to list all the laboratories
that conduct each of the tests available in the database, since the purpose
of the report is to identify new tests and the availability of published
studies for each of the identified test. |
2 |
Results |
See comments on table 2 in the Tables section
below. |
|
2 |
Discussion / Conclusion |
Last page refers to "this comprehensive
list of genetic tests," which seems at odds with the caveats and limitations
detailed in the same section. Specifically, I don't know how the list
can be characterized as comprehensive with any degree of certainty. This
is not a criticism of methodologies used, simply a suggestion to describe
the results in more accurate detail. |
Thank you, we have reworded the sentence. |
2 |
Tables |
See comments on table 1 in Methods section
above. Table 2 is very informative, however, the authors may want to consider
splitting the purpose column into multiple columns with each individual purpose
written out completely (using vertical text alignment), and tick marks or
bullets used to indicate which tests (rows) correspond to each purpose. This
would obviate the need for readers to refer to the legend to differentiate
between P, Pp, and PGx, for example. Also in table 2, some test names
have a TM symbol while others have an ® symbol. Since I assume that the
intended audience for the report consists primarily of those with clinical
or scientific, rather than legal, expertise, it could be helpful to discuss
what significance, if any, can be attributed to the difference. |
We have edited the table to obviate the need
for readers to refer to the legends. The tests are indicated with ™ and ® as
reported in individual Websites. |
2 |
Appendices |
Ordinate scales on the Medline search charts
may be confusing to some readers, since they are not consistent between
different tests (some don't begin at 0, others range from 0.0 to
1.0). Trend lines never go down, so I assume the measure of hits is cumulative
for each year, rather than being categorical by publication date, but this
should be specified. In some cases I felt the charts could be omitted
and results described in text (for example when publication numbers are
very low or when no publications that are returned with the selected search
string. |
At the suggestion of many reviewers we have
omitted the graphic plots. |
2 |
References |
Need a space in reference 4, after the first
period. Also need a period at the end of reference 4. |
We have corrected this. |
3 |
General |
Horizon scanning for health-related genetic tests is challenging because
the development of these tests is rapidly evolving and decentralized, involving
government, academic, and commercial entities. The draft report aims to
summarize key information on genetic tests currently available for clinical
use in cancer. The information in the report is valuable but is likely
to become quickly outdated: comparison with the last AHRQ Technology Assessment
of genetic tests in cancer (2006) shows how quickly the field is changing.
A more continuous horizon scanning process, together with an online database
(such as the GeneTestTracker) that could be continuously updated and made
available to a wider range of users, would be more useful than a periodic
report published at infrequent intervals. |
The database is continuously updated and we have clarified that in the
text and results section. |
3 |
Executive summary |
This draft report does not include an Executive Summary. |
Thank you, it is now included. |
3 |
Introduction/
Background |
The first paragraph clearly enumerates the different ways that genetic
tests can be used in cancer, i.e., in screening, diagnosis, risk stratification,
therapeutic management, and as a clinical decision-making tool to aid disease
monitoring and prognosis. Definition of these categories is very important
in evaluating the validity and utility of cancer genetic tests, especially
those that have been proposed for multiple uses (e.g., both therapeutic
management and prognosis) because the relevant evidence depends on the
proposed use. Although full definitions are provided in the Methods section,
I'm glad that the authors have drawn attention to this point in the
Introduction. |
Thank you. The report does not assess clinical validity or utility
of the tests in this report. |
3 |
Methods |
In addition to summarizing "all newly identified tests since 2006," it
would be helpful to provide a list of tests reviewed in 2006 with an update
on their status—e.g., to note whether in the interim, they have been
approved by FDA, modified by the test developer, or taken off the market.
That would provide users of the report with a comprehensive list of tests
meeting the inclusion criteria listed on pg. 10.
The SACGHS definition of genetic tests provided on pg. 9 is not really
adequate for this report. Although the definition includes "acquired" genotypes,
the purposes it describes for genetic testing are almost entirely from
the clinical genetics perspective, which focuses on heritable diseases.
As explained in the Introduction, "Genetic tests for cancer differ
from genetic tests for noncancer conditions in the relatively larger
number of tests for somatic mutations." As noted on pg. 10, the
report "excluded tests that are performed for conditions that result
in early death before reaching adulthood, such as metabolic or heritable
disorders." The authors should at least make note of the discrepancy,
if not point out the need for a more comprehensive definition.
A word seems to be missing from this sentence on pg. 10: "We summarized
all genetic tests that we found [that?] can be used to
provide diagnostic and prognostic information, monitor patient status,
or detect disease recurrence."
Google News searches (described on pg. 13) do not use the same query structure
as PubMed. The query "gene OR genetic OR genomic test OR epigenetic" in
PubMed would be represented in Google News advanced search as Find
results with at least one of the words "gene genetic genomic
epigenetic." It's not clear why the word "test" would
follow "genomic" in either query—it seems that it should
be added with AND to the PubMed query and excluded from the Google query
as too non-specific. The Google query equivalent to "FDA cleared
test" would be Find results with all of the words "FDA
cleared test." The search strategy should be described more precisely,
including the frequency with which e-mail alerts were reviewed, especially
because many news links are ephemeral and inaccessible after a short time.
Were the laboratory Web sites (listed on pg. 14) searched regularly or
only once?
How does the horizon scanning process treat multiple commercial names
for the same test (e.g., when a test has been licensed from one company
to another)? How does it deal with changes to a test that keeps the
same name (e.g., when additional SNPs are added to a genotype test)?
Details of the development of GeneTestTracker (pp. 16-18) seem somewhat
superfluous to the report, especially because it appears that this is an
in-house system, available only to AHRQ and CMS users. The system was already
described in the last AHRQ report on noncancer genetic tests. If this online
database will be made accessible to a wider group of users, the software
development project could be published in a citable informatics journal. |
We have added how many tests that were in development have matured to
a clinical application since 2006 and which of those are approved by the
FDA. However, it is difficult to identify how many were modified by the
test developer or were taken off the market (except for one) without personal
communication with the companies. Such communications can be very useful
for the grey literature process, but are out of the scope of the current
work assignment.
The SACGHS definition does include somatic mutations. We have edited this
section for the most recent definition.
We have edited this sentence.
The Google News does allow searches to be conducted using "OR" and
additional search terms can be added to the Google email alert. We have
removed "OR" within the test because it resembles that of
PubMed searches. We view email alerts once a week.
Those are great questions, we can only identify those changes to genetic
tests only through contact with the companies or a company voluntarily
deposits such information. Currently we do not have mechanisms to identify
multiple commercial names to the same test as well as any changes made
to the genetic test. We have added this as a limitation to the Web -based
horizon scanning process. |
3 |
Results |
The report states (pg. 19) that the GeneTestTracker contains information
on 100 genetic tests (in 149 test-disease combinations); of these, 38 are
cancer-related tests identified since 2006. How do these results correspond
with those reported in earlier AHRQ horizon scans for genetic tests? For
example, the 2006 report identified 104 cancer-related genetic tests "in development";
the 2010 report on noncancer tests identified 22 new tests since 2007.
It's not clear how these results fit together or how the GeneTestTracker
is updated. Can it be used to describe the evolution of specific tests
(or the field as a whole) or does it provide only cross-sectional data
(i.e., more details on tests described in the published reports)?
We conducted a pilot project (also based on Google News Alerts) to assess
the former question and encountered several challenges (go to
Horizon
scanning for new genomic tests, PMID: 21233720, DOI: 10.1097/GIM.0b013e3182011661).
During a 6-month period, we identified 188 new, health-related genetic
tests, of which 122 (or approximately 2/3) were related to cancer; after
the pilot phase, we continued to identify 2-3 new tests per week. Although
we applied less stringent eligibility criteria (to capture tests that
were still in development or just being introduced for clinical use),
these findings reflect a very rapidly developing field. |
The 2006 report identified "tests in development" contacting
various companies to identify 104 cancer-related tests in development.
Only if these tests have matured to clinical use are added to the electronic
database, but those that are still in development are currently being tracked
to identify their status. |
3 |
Discussion/
Conclusion |
Some of the issues mentioned above could be addressed briefly in the
Discussion. |
Thank you we have added many of your valuable points to our discussion |
3 |
Tables |
No additional comments. |
|
3 |
Figures |
Figure 2 is not needed because it duplicates (with less detail) information
already presented in Table 2. |
Deleted. |
3 |
Appendices |
The one-page summaries provide key information about each test; however,
they are not easy to search or analyze. Is there any significance to their
order? Could it be changed to correspond with the order in Table 2 (i.e.,
breast cancer first, then prostate cancer, etc)? Ideally, readers would
be allowed to use the GeneTestTracker database for searching and access
to more detailed information retrieved for the technology assessment.
The charts of "Medline hits" are dramatic but they take
up a lot of space. It might be more helpful to show these data in a table.
It would be easier to make comparisons among tests (e.g., to see which
ones might have sufficient data available for a systematic review) using
numbers. Vastly differing scales on the charts highlight trends while
down-playing the actual numbers of citations. |
We have rearranged the one-pagers according to the table 2.
At the suggestion of many reviewers, we have omitted the graphic plots. |
3 |
References |
Suggest referencing other attempts to summarize information on genetic
tests, such as: Kuehn BM. NIH launching genetic test registry. JAMA 2010;303:1685. |
Thank you. We have added in the discussion. |
4 |
General |
A glossary of the genetic/genomic terms used would be a welcome addition. |
Many of the terms are explained within text. |
4 |
Methods |
A major omission in the search strategy is the test directory maintained
by the Association for Molecular Pathology (AMP) http://www.amptestdirectory.org/index.cfm
Unlike the GeneTests Web site which mostly includes tests for inherited
forms of cancer, the AMP directory includes genetic tests for both inherited
and acquired cancer. Although a wide range of reference laboratory and
manufacturer Web sites were included, it is likely that the many hospital
and university-based laboratories that provide genetic tests for cancer
were missed with this search strategy. |
We have searched academic laboratories with limited yield for new tests.
We have added AMP.org as one of our resource for current and future horizon
scanning. |
4 |
Results |
There are a number of notable omissions in the list of available tests
including KRAS for NSCLC and CRC, BRAF in CRC, ERCC1 in NSCLC, deCODE ProstateCancer,
DecisionDx-GBM, DecisionDx-UM, CYP2D6 in breast cancer, JAK2 in myeloproliferative
disorders, PathfinderTG (multiple applications), Previstage GCC in CRC,
TargetNow Molecular Profiling test, THEROS CancerTYPE ID. |
Thank you, we have included tests that provided complete one-pager information. |
4 |
Discussion / Conclusion |
Limitations of the study are appropriately noted but perhaps greater
emphasis on the dynamic nature of genetic/genomic testing for cancer applications
is needed and a more definite schedule for updating both the existing information
sheets and the addition of new tests is needed. At a minimum such a scan
should be performed annually |
Yes, the updates are ongoing and we have clarified in the method section. |
4 |
Figures |
Figure 2 does not seem to add any useful information to the report.
I would recommend omitting it |
We have deleted the figure. |
4 |
Appendices |
Suggestions for the test information sheets:
- Expand description
of test; define terms used.
- Provide a date
for the literature search.
- Delete figure
that shows increase in publications—this will not be meaningful
to most users.
- Include a few
key abstracts or at least links.
- Write sources
in proper citation style; include links to Web sites, if used.
|
The database searches the last date of finalizing the draft report (March
2011). The current output is directly from the database. The current database
is structured similar to the Excel® and Word® databases included in the 2006
report. |
4 |
References |
This reference list seems very short—I assume more resources were
used? If so, they should be cited. Dates of access of Web sites should be included. |
The Web sources are listed within the text. |
1. Peer reviewers are not listed in alphabetical order.
2. If listed, page number, line number, or
section refers to the draft report.
3. If listed, page number, line number, or
section refers to the final report.
Return to Contents
Table 2: Public Review Comments
Reviewer1 |
Reviewer Affiliation2 |
Section3 |
Reviewer Comments |
Author Response4 |
1 |
College of American Pathologists |
General |
The College of American Pathologists (CAP), the Nation's largest association
of Board-certified pathologists, appreciates this opportunity to provide
comments on the Agency for Healthcare Research Quality (AHRQ) Update on
Horizons Scan of Genetic tests currently available for Clinical Use in
Cancer (November 2010). The College is a national medical specialty society
representing 17,000 pathologists who practice pathology and laboratory
medicine. The College's Commission on Laboratory Accreditation through
its Laboratory Accreditation Program (LAP) is responsible for accrediting
more than 6,000 laboratories worldwide. Our members have extensive expertise
in providing and directing laboratory services and serve as inspectors
in the laboratory accreditation program.
General Comments:
The report would be more appropriately titled Update on Horizons Scan
of Molecular Diagnostic Tests currently available for Clinical Use in Cancer. The
use of the terminology "genetic test" is inappropriate—a terminology
consistently used in this document to refer to ACQUIRED somatic mutations
in cancer or pre-cancer cells. Though the Introduction appropriately
differentiates genetic and somatic mutations, the authors create confusion
by using the SACGHS definition which is broad enough to include any molecular
test used for cancer patients. In addition, the individual summaries
in the Appendix fail to note which tests are for genetic variation and
which are for somatic mutations which we believe is an important distinction.
The College is concerned that AHRQ would publish a report composed by
a group that inappropriately fails to include relevant stakeholders. The
authorship of any report involving lab tests should include pathologists
who are providers of the spectrum of lab tests covered in the report. As
we have noted before, the College is concerned about the performance of
horizon scans and other literature reviews divorced from an understanding
of the clinical use of the tests which can result in incorrect categorization
of tests. |
We have been using the SACGHS definition for the past 5 years. The definition
is comprehensive and fits very well within the range of products that have
been commercially available under "genetic tests." Our tests
include both molecular as well as somatic mutations genetic / genomic tests,
when available. The purpose of our report is to succinctly summarize the
results of horizon scanning of new genetic/genomic tests. Further classification
will be adequately addressed during a focused systematic review.
The focus of this report is to catalogue the tests available and marketed
commercially. We do involve stakeholders, when a test is reviewed in detail
for analytical validity, clinical validity and clinical utility through
a systematic review of published studies. |
1 |
College of American Pathologists |
Introduction/
Background |
The introduction provides a good description of the differences between
genetic and somatic mutation, however, this important distinction was not
addressed beyond the introduction and should be noted for each test summary
in the Appendix. |
Thank you. |
1 |
College of American Pathologists |
Methods |
Literature Search: The authors should broaden their search to include
additional resources. The Web searches used for data discovery specifically
excluded the "gold standard" source for finding cancer molecular diagnostic
tests in real-world service labs, namely the AMP test directory (amp.org).
GeneTests, heavily emphasized as a prime data source, specifically EXCLUDES
tests for acquired cancer-associated mutations. In addition, the CAP Proficiency
testing products catalog would be an excellent resources. The catalog lists
oncology tests for which proficiency testing (PT) is available thru CAP
for tests that are used in clinical settings (focus on DNA or RNA based
tests, but not the many other tests that CAP members provide like morphology
and lipid/protein-based tests relevant to oncology).
The emphasis seems to be misplaced onto the NUMBER of new cancer tests
that can be found rather than the much more appropriate (and harder
to get) data on the VOLUME of such testing (i.e., sample numbers) in routine
clinical practice which will be a much better surrogate for clinical
utility. Similarly, the emphasis on number of Medline hits seems quite
misplaced, Medline hits being, by definition, a surrogate for quantitating
perhaps research emphasis, but certainly not clinical usage/utility.
Clinical Application of Tests: Definitions for terms used in the report
are important. "Therapeutic management" includes all kinds
of therapy from drugs to behavioral therapy to nutrition counseling. The
terms screening, diagnostic, monitoring, prognostic and predictive are
typically used to categorize oncology tests. There needs to be
explicit clarity between predictive and prognostic tests. The report
currently has a category of "prevention" that includes predictive testing.
A specific definition of pharmacogenetic tests is also needed as this term
is used inappropriately in some summaries in the Appendix. |
We relied on several sources including GeneTests.org.
Thank you for suggesting the Web site (amp.org). We will review the list
of genetic tests against those currently captured in our database and add
any new tests that we may have missed out.
The purpose of conducting Medline hits is to assess available evidence
for a topic review through a systematic review and analysis. The purpose
of this horizon scanning is not to assess the volume of testing or to assess
the clinical utility.
We have clarified the terminologies and we have changed pharmacogenetic
to therapeutic management. |
1 |
College of American Pathologists |
Results |
Table 2 The list of tests does not include prognostic brain tumor markers
such as deletions on chromosome 1p and 19q or testing for NF1 which is
associated with numerous cancers (malignant peripheral nerve sheath tumors,
gliomas, sarcomas, neuroendocrine tumors, and leukemia). Patients with
these malignancies commonly do not develop malignancies until after reaching
adulthood and therefore do not meet the exclusion criteria for conditions
that result in early death before reaching adulthood. The College believes
these tests and others were missed due to the methodology and focus on
commercial laboratories. There are a number of analytes that are not listed
in Table 2 for which the college offers PT.
While excluding the tests noted above, the list includes such test as
cytokeratin 20 (CK20) and alpha fetoprotein (AFP) that are not genetic
tests, or even somatic mutations at all, but rather indicators of cell
type and differentiation. While an important test, the digene High-Risk
HPV HC2 DNA Test is neither a genetic test nor a somatic test but rather
tests for an infectious agent etiologically related to cervical cancer
and which is used in the context of cytologic evaluation of cervical specimens
in some women.
Electronic Database We noted that the electronic database created for
this reports duplicates some of the efforts of the National Institute of
Health to create a genetic testing registry. We commend the Tufts
Medical Center Evidence-base Practice Center for developing this resource. |
Preference of entry is usually given to common cancers that are more applicable
to the older adults. Thank you we will add tests suggested, since the update
is ongoing.
There are many more tests listed in our previous report, and this is an update
to the report published in 2006.
The one pagers are available in the pdf/word format at the following
Web link:
http://archive.ahrq.gov/clinic/ta/gentests/
We have used a broad definition put forward by SAGCHS. Their definition
of a genetic test also includes biochemical tests for gene products such
as enzymes and other proteins.
We have deleted the digene High-Risk HPV HC2 DNA Test since this falls
under the category of non-medical genetic testing mainly for the identification
of the presence of animal/viral materials.
The efforts by AHRQ/CMS to create and maintain this database precede
some of the recent efforts of the National Institute of Health to create a
genetic testing registry. These reports have been ongoing for the past five
years with a focus to identify topics for a thorough future evidence evaluation.
To this extent we have shared our database with the NIH. |
1 |
College of American Pathologists |
Discussion/ Conclusion |
The CAP appreciates this opportunity to comment on this Updated Horizon
Scan. Due to the short review period, we could not provide a more detailed
review of the one page summaries in the Appendix but hope that overall our
comments are helpful. If you have any questions on the issues raised herein,
please do not hesitate to contact, Fay Shamanski, Ph.D., Assistant Director,
Public Health and Scientific Affairs (202-354-7113 / fshaman@cap.org) |
Thank you for the contact information. |
1 |
College of American Pathologists |
Appendices |
While we did not have sufficient time to provide detailed edits in general
we found the purpose of the tests to be inappropriately described in some
cases. In particular, some tests were listed as pharmacogenetic that
are not involved in drug metabolism but rather used for therapeutic management. Pharmacogenetic
implies both that genetic variation is inherited and that it is involved
in drug metabolism(1). For example, DPD 5-FU GenotypR (TM) fits
the definition of a pharmacogenetic test, while tests such as Her2 neu
overexpression are probably more accurately described as used for therapeutic
management.
(1) For example, one definition is the heritable component of variation
among individuals with respect to drug response or adverse reaction. www.nature.com/nrg/journal/v5/n5/glossary/nrg1325_glossary.html |
We have added the therapeutic management since this is similar to our categories. |
2 |
Bristol-Myers Squibb Company |
|
Bristol-Myers Squibb is a global biopharmaceutical company firmly focused
on its Mission to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases. We are proud to acknowledge
and support the initial Draft Report entitled "Update on Horizon Scans of
Genetic Tests Currently Available for Clinical Use in Cancers." We appreciate
the opportunity to provide comment(s) on this research effort.
We believe the attempt to capture the field of genetic testing via a Web
search is limited in that many of the tests reported were not based on
the manufacturer's information, but on secondary Web sites that reported
about the tests without attribution to the manufacturer's name or Web site.
Additionally, the term "genetic" testing is utilized throughout the document, yet, a number of the tests are protein based and not genetic while
the inclusion criteria is unclear. As a Web search was used, it cannot
be assessed how well they identified all tests available. In table 1,
the listing of Web sites used does not include a number of major manufacturers,
with a corresponding lack of tests reported in the appendix. There
are several hundred Diagnostics manufacturers, and the number of tests
offered through CLIA labs is virtually impossible to determine. Lastly,
it would be useful to have the ability for the public to search the Tuft's
GeneTest Tracker database system and obtain high level information on
these types of tests. |
The attempt to identifying genetic testing through Web searching has been
replicated by a recent publication from the members at the CDC (Gwinn et
al PMID:21233720). The purpose is to identify as many tests as possible with
the caveat that there are many tests available that would not be captured
within the sources interrogated. This limitation has been added to our discussion
section.
We are using a broad definition as put forward by the SACGHS. This definition
does include the analysis of human proteins and certain metabolites, which
are predominantly used to detect heritable or acquired genotypes, mutations,
or phenotypes.
There are many more tests listed in our previous report, and this is an
update to the report published in 2006.
The one pagers are available in the pdf/word format at the following Web link:
http://archive.ahrq.gov/clinic/ta/gentests/ |
3 |
Amgen Inc. |
|
Amgen Inc. (Amgen) wishes to provide comments to the recently-released
Agency for Healthcare Research and Quality (AHRQ) draft Technology Assessment
(TA) entitled, "Update on Horizon Scans of Genetic Tests Currently
Available for Clinical Use in Cancer," issued for public review and comment
on December 22, 2010. This letter is intended to emphasize the importance
of including Kristen-RAS (KRAS, a member of the rat sarcoma virus (ras)
gene family of oncogenes) testing in any comprehensive review of genetic
tests currently available for clinical use in cancer. As a science-based,
patient-driven company that is committed to using evidence-based science
and innovation to dramatically improve patient's lives, Amgen respectfully
submits this short comment letter to help support and supplement the careful
analysis completed by the team at the Tufts-New England Medical Center
Evidence-based Practice Center (EPC).
KRAS mutation analysis was one of the topics discussed in the June 7,
2010 Technology Assessment report (Project ID: GEN0609) entitled 'systematic
Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6
for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal
Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid
Leukemia'. As reviewed, KRAS analysis is an important pharmacogenetic test
for colorectal cancer patients being considered for anti-EGFR therapy.
This finding was arrived at through analysis of several randomized controlled
trial-based analyses of progression-free survival, where treatment benefit
was found to be unlikely for colorectal cancer patients whose tumors carried
KRAS mutations, in comparison to colorectal cancer patients whose tumors
were KRAS wild-type. And, as Amgen previously publicly commented
on this TA (Amgen comment letter dated February 12, 2010), two additional
phase 3 chemotherapy/anti-EGFR combination studies have been completed
and subsequently published (footnotes 1 & 2). In both studies, panitumumab
in combination with either FOLFOX or FOLFIRI significantly improved progression
free survival (PFS) in patients with KRAS wild-type tumors, including in
1st line use. In contrast, patients with KRAS mutant tumors did
not show an improvement in median PFS. In the 1st line study, in
patients with tumors harboring activating KRAS mutations, PFS was significantly
inferior in the panitumumab arm. Further underscoring the importance
of KRAS pharmacogenetic testing, the labels for this class of drugs were
modified to state that retrospective subset analyses of metastatic colorectal
cancer trials have not shown a treatment benefit in patients whose tumors
had KRAS mutations in codon 12 or 13 (footnote 3).
We appreciate AHRQ's and the Tufts-New England Medical Center EPC's careful
consideration around either formally adding KRAS testing to this report,
or, at least clearly referencing this important cancer test in the final,
published technology assessment. Furthermore, we look forward to continuing
to work with AHRQ, CMS, as well as with our industry colleagues and others,
to further explore this rapidly evolving and promising field of pharmacogenomic
testing in cancer. As your interest allows, we would welcome the
opportunity to provide additional information in support of your on-going
efforts. Please contact Sarah Wells Kocsis by phone at (202) 585-9713
or by E-mail at wellss@amgen.com if you have any questions regarding our
comment, or, wish to arrange a meeting.
Footnotes:
1. Douillard, J.-Y. et al. Randomized phase III study of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus
FOLFOX4 alone as first-line treatment in patients with previously untreated
metastatic colorectal cancer: The PRIME study. J Clin Oncol 28, 4697-4705
(2010)
2. Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil,
leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line
treatment in patients with metastatic colorectal cancer. J Clin Oncol
28, 4706-4713 (2010)
3. FDA Press Release July 17, 2009, describing Class Labeling Changes to
anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix)
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm |
We thank you for the comments as well as for the contact information.
We would like to clarify this is a horizon scan report listing tests that
are currently available for clinical practice. This is not a full systematic
review.
We thank you for the comments as well as for the contact information.
We would like to clarify this is a horizon scan report listing tests that
are currently available for clinical practice. This is not a full systematic
review. We have included references that are needed for grey literature
search purposes. |
4 |
University of Ottawa |
General |
This draft only has come to my attention within the past week, so I
have not had the opportunity to do a thorough review.
I was particularly struck by some of the one-page summaries in Appendix
A, notably for PSA (page 28 and page 47), and high-risk HPV (HC2; page
46).
I can see that PSA and related testing fits in with the definition of
genetic testing presented on page 9. The test for high-risk HPV is a test
for specific types of viral infection, so it does not fit the "human" definition
on page 9. That said, it is a test that looks at variant types of viral
DNA (and arguably this becomes problematic when this DNA is integrated
with that of the human host, although the test does not test for integration
per se).
I'm aware that there are more tests for HPV available, but I assume that
these were not included because they have not been cleared by FDA, or are
in status of pending clearance. |
Thank you for pointing us this error. We have deleted the digene High-Risk
HPV HC2 DNA Test since this falls under the category of non-medical genetic
testing mainly for the identification of the presence of animal/viral materials.
Other tests do qualify based on the definition chosen for the horizon scanning. |
4 |
University of Ottawa |
Appendix A |
I note that the purpose of test 2 (complexed PSA, page 28) is listed
as "diagnosis and monitoring" in adjunctive testing with DRE,
but the description given suggests the test would be applicable to screening.
The purpose of test 19 (free PSA, page 47) is listed as "screening,
diagnostic". Are these the same tests that are used in PSA testing
in annual physicals? It would be very helpful to clarify this, and refer
to the evaluations of PSA screening
http://www.ahrq.gov/clinic/uspstf/uspsprca.htm. and
Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and Harms of Prostate-Specific
Cancer Screening: An Evidence Update for the U.S. Preventive Services Task
Force. Evidence Synthesis No. 63. AHRQ Publication No. 08-05121-EF-1. Rockville,
Maryland: Agency for Healthcare Research and Quality. August 2008.
With regard to test #18 (HC2 for high-risk HPV), note that this is a test
for viral infection. It is highly sensitive for detection of cervical intraepithelial
neoplasia (stage 2 or more severe). CIN is a precancerous lesion. This
does not quite fit in with the definition of prevention on page 11, as
it is not detecting inherited susceptibility in persons who do not have
cancer, and although it does pick up early stage cancer, I think a key
property is detection of CIN2/3 along the lines of the Pap test. There
are many evaluations of HPV testing both as a primary screening test, and
in triage of women with low-grade cervical cytological abnormalities (e.g.
by Marc Arbyn and colleagues; I note also that there is a Cochrane review
group http://www.hpv2009.org/CochraneWebsite.pdf) [I must declare an interest
because of my involvement in the UK TOMBOLA trial] |
We have included tests that fit the inclusion criteria per our definition.
Further clinical validity or utility issues are best addressed during a
systematic review.
We have deleted the digene High-Risk HPV HC2 DNA Test. |
5 |
Technology Evaluation Center, Blue Cross Blue Shield Association |
General |
The Blue Cross Blue Shield Association Technology Evaluation Center
has reviewed the draft technology assessment, Update on Horizon Scans of
Genetic Tests Currently Available for Clinical Use in Cancers, and submits
the following comments for consideration:
1) As noted, "The current
report updates the database of genetic tests for cancer conditions... for all newly identified tests since 2006" and provides a listing
and individual test summaries for only those new tests. The reader
is referred to the 2006 test listing in citations and via a Web link in
Appendix A. However, a synthesized list would constitute a more useful
and comprehensive update with indications of which tests are new since
2006, which 2006 tests are still available, and which are no longer available
(e.g. PreGen).
2) The 2006 report also
provided a "tests in development" list which this draft does not update.
It would be helpful to know which of the 2006 listed tests in development
moved to 2010 tests available list, which are still in development, and
which are no longer in development. Will an updated "tests in development
list" be added to this report?
3) This draft assessment
describes a "GeneTestTracker" database to which "users can add a new genetic
test by simply clicking the 'add new' button." It is not clear how accessible
this 'password protected' database will be, who will have password access
to add new tests, and who will curate the information. The report
does note that "CMS would like the report and the accompanying database
to be a ready reference for their internal discussions in this area and
for decisions on future topics for systematic reviews." Does that
mean that the database is limited to CMS use only? That would preclude
the potentially broader utility of such a database. In addition,
this database begins to duplicate, in concept (and limited to cancer) the
proposed NIH Genetic Test Registry. Is there discussion of integrating
the two databases?
4) The new test listing
seems to be missing tests; see below for several quickly and randomly picked
examples that we could not find in either the 2006 or 2010 reports (note:
although some diagnostic laboratory Web sites may not detail the components
of multi-gene profiles, where such tests are commercially available, test
indications are stated, and it is clear that the test is nucleic acid-based,
it would seem to meet inclusion criteria).
5) Regarding grey literature
sources, GeneTests.org (focused largely on diseases of Mendelian inheritance)
and commercial laboratories are certainly viable sources, but there are
other groups with well-tested, ongoing grey literature search mechanisms
for current information on genetics and genetic tests who could have been
consulted or perhaps made partners in this update (e.g. the Office of Public
Health Genomics at the Centers for Disease Control and Prevention).
6) The EGAPP Working Group
maintains a running list (although not necessarily comprehensive) of available
genetic tests on its public Web site. This list does not appear to
have been consulted. As examples, the PI3K and JAK2 tests listed
below appear in the EGAPP Web site listing.
Random examples of tests not on either 2006 or 2010 genetic test lists:
Response Genetics has developed PCR-based genetics tests—ResponseDX: Lung?,
ResponseDX: Colon?, ResponseDX: Gastric?—to help physicians with therapeutic
treatment decisions for patients with non-small cell lung cancer (NSCLC),
colorectal cancer (CRC) and gastric cancer. (http://www.responsegenetics.com/).
ALK Gene Rearrangement (Clarient)
PI3K mutations (Clarient)
Breast Profile (CombiMatrix Diagnostics; http://www.cmdiagnostics.com/oncology/index.html)
"Our Breast Profile offers all of the benefits of HER2 PRO, plus the added
clinical utility derived from a complete genomic analysis of each patient's
unique tumor DNA."
Heme Profile (CombiMatrix Diagnostics)
"The DNAarray assay for Hematologic Malignancies such as Chronic Lymphocytic
Leukemia (CLL) and MyelodysplaStic Syndrome (MDS) combines the high resolution
of FISH with the genome-wide copy number assessment found in traditional
cytogenetics testing."
Tumor Profile (CombiMatrix Diagnostics)
"The DNAarray Tumor Profile allows for the rapid identification of key
amplifications and deletions across the genome, which can yield important
prognostic and predictive information for both physician and patient."
JAK2 (widely available) Confirm diagnosis in individuals with clinical
suspicion of myeloproliferative disorders
ColoSure Colorectal Cancer Detection (Vimentin Gene Methylation
Assay; LabCorp) |
We have added additional information on the evolution of genetic tests
in the results section.
The Office of Public Health Genomics at the Centers for Disease Control
and Prevention published paper utilizes similar approach to our literature
search and they do count tests both that have matured to clinical use and
that are currently listed as in development. The members of this office
are included as reviewers in this report and their input at this stage
of review is insightful.
The members of the Office of Public Health Genomics at the Centers for
Disease Control and Prevention have been peer reviewers of our report.
Thank
you, we have added additional tests with complete one-pager information. |
6 |
Novartis Oncology |
|
Dear AHRQ Committee members,
Novartis Oncology, a business unit within Novartis Pharmaceuticals Corporation,
is pleased to submit comments for consideration by the Committee as it
discusses the impact of pharmacogenetic testing on the health outcomes
of specified groups of patients with cancer. Specifically, we are submitting
comments against the recommendation to use KIT Asp816Val Mutation Analysis
as a pharmacogenetic test in patients with chronic myeloid leukemia (CML)
who are resistant to imatinib therapy. In support of this position, we
will summarize the current evidence regarding the role of imatinib on the
oncoprotein BCR-ABL in CML, as well as its action on off-target kinases
such as c-KIT and platelet-derived growth factor receptor alfa (PDGFRA).
In addition, we appreciate the opportunity to review the effect of mutant
c-KIT on specific cancers.
CML and BCR-ABL
CML is a clonal disease characterized by the presence of the Philadelphia
(Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively
active tyrosine kinase, that is present in >90% of patients.(1) The
Ph stems from a reciprocal chromosomal translocation of the BCR gene
from chromosome 9 and the ABL gene from chromosome 22. The BCR-ABL fusion
gene drives the pathogenesis of CML.(2)
The development of selective BCR-ABL tyrosine kinase inhibitors (TKIs),
including Gleevec (imatinib mesylate) and more recently Tasigna (nilotinib)
and Sprycel (dasatinib), have positively impacted clinical outcomes in
CML, and have become the current standard of care for treating newly diagnosed
patients with Ph+ CML.(3) Most patients who receive TKI therapy for CML
in chronic phase now achieve a complete cytogenetic response (CCyR) during
the course of treatment. Clinical studies have demonstrated an overall
survival rate of 85%, and a freedom from progression to AP or BC of 92%
at 8 years on imatinib therapy.(4, 5, 6) The clinical use of specific BCR-ABL
inhibitors has significantly improved prognosis, response rate, overall
survival, and patient outcome in CML patients compared with previous therapeutic
regimens.(1)
Although point mutations in the ABL-tyrosine kinase domain contribute to
imatinib resistance,(7) a review of published literature and internet search
revealed a paucity of published scientific evidence documenting the presence
or incidence of KIT Asp816 Val mutation in patients with CML. Furthermore,
no published scientific evidence suggests that the KIT Asp816 Val mutation
confers clinical or prognostic significance in patients with CML. There
is no published evidence documenting the sensitivity and validity of this
genetic test in patients with CML or that the results of this test can
provide therapeutic guidance for practitioners.
Imatinib inhibits BCR-ABL, PDGFRA, and c-KIT Imatinib not only inhibits
BCR-ABL but has been found to be almost equally potent in vitro against
PDGFRA, and c-KIT receptor tyrosine kinases.(8) KIT is a receptor tyrosine
kinase that is functionally relevant for hematopoiesis, mast cell development
and function, gametogenesis and melanogenesis.(9) Imatinib targets KIT
at the ATP-binding site, thereby maintaining the receptor in a nonactivated
state.(10) While in humans, loss-of-function KIT mutations have been associated
with piebaldism—an autosomal dominant condition characterized by depigmented
patches of skin and hair—gain-of-function KIT mutations are usually acquired,
and have been associated with myeloid malignancies including core binding
factor acute myeloid leukemia and systemic mastocytosis (SM), germ cell
tumors, gastrointestinal stromal tumors (GIST) and sinonasal T cell lymphomas.(9)
Imatinib as treatment for GIST
GIST are the most frequent mesenchymal tumors of the gastrointestinal (GI)
tract and represent <1% of all malignant GI neoplasms.(11) KIT mutations
are detected in about 75% to 85% of GIST patients, while PDGFRA mutations
are found in 5% to 10%.(12) Since KIT and PDGFRA mutations are central
events in GIST pathogenesis, and imatinib was known to act on these receptors,
imatinib was evaluated in the treatment of patients with GIST whose tumors
expressed activated c-KIT, with promising efficacy and safety.(13) Following
clinical trials, imatinib was approved for the treatment of GIST in February
2002.(11) Resistance to imatinib in patients being treated for GIST can
generally be ascribed to the presence of secondary mutations, usually
affecting the catalytic domain of KIT. The Val654Ala substitution, affecting
the ATP-binding pocket of the kinase, is one of the most commonly detected
mutations.(11) Sunitinib has recently been approved as second-line therapy
for patients with GIST who became resistant to imatinib treatment.(14)
Systemic mastocytosis and the KIT Asp816Val mutation Stem cell factor
(SCF)-dependent activation of KIT is critical for mast cell homeostasis
and function. However, when KIT is inappropriately activated, accumulation
of mast cells in tissues results in mastocytosis.(10) KIT Asp816Val is
the most prevalent KIT mutation in mast cell disease and occurs in more
than 90% of patients with systemic mastocytosis (SM).(9) Detection of a
mutation at the 816 codon is included as 1 of the minor diagnostic criteria
for systemic mastocytosis in the World Health Organization (WHO) classification
system for hematopoietic neoplasms and is also of therapeutic relevance,
as it confers resistance to imatinib.(15, 16) Notably, SM with PDGFR mutations
are highly sensitive to treatment with imatinib, whereas the more common
SM containing KIT Asp816Val mutations are usually resistant to imatinib,
because of an induced conformational change at the ATP-binding domains
of KIT, which confers constitutive activity(17) and interferes with the
association of imatinib and the receptor.(18, 19) Determination of the
presence or absence of a KIT Asp816Val point mutation by cytogenetic analysis
in patients with SM is therefore important for establishing a diagnosis,
as well as for guiding pharmacologic therapy.(20, 21) A similar pharmacological
profile has been reported for the imatinib mimetics; therefore, development
of KIT kinase inhibitors that overcome the drug-resistance associated with
the KIT Asp816Val mutation remains a focus of ongoing research.(22)
Although SM can occur concurrently with myeloid diseases such as CML or
chronic myelomonocytic leukemia,(23) there is no literature documenting
the incidence, implications or prognosis in patients with concurrent CML
and SM with a KIT Asp816Val point mutation.
Conclusion
In conclusion, while determination of the presence or absence of the
KIT Asp816Val mutation in patients with SM offers a useful adjunct in establishing
a diagnosis and therapeutic treatment plan for this complex and heterogeneous
disease, there is no evidence or rationale to support testing for this
mutation in patients with CML, as recommended in the draft Update on
Horizon Scans of Genetic Tests Currently Available for Clinical Use in
Cancers. Although imatinib simultaneously targets BCR-ABL and c-KIT,
and is considered standard therapy in the treatment of CML, there exists
no published scientific evidence that the KIT Asp816Val mutation has
any relevance to patients with CML, and therefore genetic analysis of
the KIT Asp816Val mutation should not be recommended for guiding imatinib
therapy in CML patients. In an era of cost consciousness, it is neither
rational nor prudent to recommend the KIT Asp816Val genetic test for
patients with CML. Furthermore, patients with CML should not be
subjected to painful, costly and unnecessary bone marrow sampling without
established clinical merit. Finally, there is no pharmacoeconomic analysis
to suggest that the information derived from this genetic test offers
valuable information that would direct clinical decisions and decrease
health care costs in patients with CML. Novartis Oncology respectfully
submits that the recommendation to use KIT Asp816Val mutation analysis
for CML patients be removed from the draft, as no evidence for using
KIT Asp816Val mutation analysis for CML or for guiding treatment with
imatinib could be identified in the scientific and medical literature.
We appreciate the opportunity to respond to your request for information
and would be happy to provide additional information and/or answer any
questions you may have on this topic. Please do not hesitate to contact
me if I can be of further assistance.
We appreciate the opportunity to submit a response. Our comments are of
a general nature; therefore, we have included our response in the "General" category.
---------References----------
1. An X, Tiwari AK, Sun
Y, Ding PR, Ashby CR, Jr., Chen ZS. BCR-ABL tyrosine kinase inhibitors
in the treatment of Philadelphia chromosome positive chronic myeloid leukemia:
a review. Leuk Res Oct;34(10):1255-1268.
2. O'Brien S, Berman E,
Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic
myelogenous leukemia. J Natl Compr Canc Netw Oct 2009;7(9):984-1023.
3. NCCN. National Comprehensive
Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous
Leukemia. Vol Version 1. 2011. Fort Washington, PA National Comprehensive
Cancer Network; 2010.
4. O'Brien SG, Guilhot
F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine
for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med
Mar 13 2003;348(11):994-1004.
5. Kantarjian HM, Talpaz
M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based
regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood Sep 15 2006;108(6):1835-1840.
6. Deininger M, O'Brien
S, Guilhot F, et al. International Randomized Study of Interferon Vs STI571
(IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression
or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemaia in
Chronic Phase (CML-CP) treated with Imatinib. Blood (ASH Annual Meeting
Abstracts). 2009;114.
7. Branford S, Melo J,
Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy
for chronic myeloid leukemia patients after imatinib failure: does the
BCR-ABL mutation status really matter? Blood 2009;114:5426-5435.
8. Buchdunger E, Cioffi
CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits
in vitro signal transduction mediated by c-kit and platelet-derived growth
factor receptors. J Pharmacol Exp Ther Oct 2000;295(1):139-145.
9. Lim KH, Pardanani A,
Tefferi A. KIT and mastocytosis. Acta Haematol 2008;119(4):194-198.
10. Jensen BM, Akin C, Gilfillan AM.
Pharmacological targeting of the KIT growth factor receptor: a therapeutic
consideration for mast cell disorders. Br J Pharmacol Aug 2008;154(8):1572-1582.
11. Pierotti MA, Negri T, Tamborini
E, Perrone F, Pricl S, Pilotti S. Targeted therapies: the rare cancer paradigm.
Mol Oncol Feb;4(1):19-37.
12. Lasota J, Miettinen M. Clinical
significance of oncogenic KIT and PDGFRA mutations in gastrointestinal
stromal tumours. Histopathology Sep 2008;53(3):245-266.
13. Bayraktar UD, Bayraktar S, Rocha-Lima
CM. Molecular basis and management of gastrointestinal stromal tumors.
World J Gastroenterol Jun 14;16(22):2726-2734.
14. SUTENT(R) (sunitinib malate) capsules.
[Sutent Prescribing Information]. July 2010 July 2010;New York, NY:Pfizer
Labs.
15. Valent P, Horny HP, Escribano L,
et al. Diagnostic criteria and classification of mastocytosis: a consensus
proposal. Leuk Res Jul 2001;25(7):603-625.
16. Jaffe ES HN, Stein H. World Health
Organization Classification of Tumours. Pathology & Genetics. Tumours
of the Haematopoietic and Lymphoid Tissues. 2001:291-302.
17. Foster R, Griffith R, Ferrao P,
Ashman L. Molecular basis of the constitutive activity and STI517 resistance
of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004;23:139-152.
18. Scheinfeld N. A comprehensive review
of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol
Feb 2006;5(2):117-122.
19. Akin C, Brockow K, D'Ambrosio C,
et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells
bearing wild-type or mutated c-kit. Exp Hematol Aug 2003;31(8):686-692.
20. Pardanani A, Ketterling RP, Brockman
SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs
in systemic mastocytosis associated with eosinophilia and predicts response
to imatinib mesylate therapy. Blood Nov 1 2003;102(9):3093-3096.
21. Valent P, Akin C, Sperr WR, et
al. Diagnosis and treatment of systemic mastocytosis: state of the art.
Br J Haematol Sep 2003;122(5):695-717.
22. Gleixner KV, Mayerhofer M, Aichberger
KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells
expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib,
and cladribine (2CdA) and evaluation of cooperative drug effects. Blood
Jan 15 2006;107(2):752-759.
23. Agis H, Sotlar K, Valent P, Horny
HP. Ph-Chromosome-positive chronic myeloid leukemia with associated with
bone marrow mastocytosis. Leuk Res 2005;29:1227-1232. |
Our introduction clearly states that the purpose of horizon scan "The
main objective of this report is to provide a broad overview with sufficient
information on each identified genetic test, and to provide a preliminary
estimate on the amount of published literature available on each genetic
test. This report is not meant to be an in-depth review of each test. Systematic
review of selected tests will be the subject of future focused reviews.
The contents in the database and in the report reflect the data obtained
from manufacturers' Web sites or other commercial Web sites, and
should not be construed as definitive clinical evidence." We have
added few more words "or as a recommendation for clinical use"
The tests are listed as those available in clinical use. The report does
not attest the clinical validity or utility of the tests.
The tests are listed as those available in clinical use. The report does
not attest the clinical validity or utility of the tests. Thus evidence
around these tests are not assessed in this report to suggest removal of
these tests.
Thank you, this report is not an extensive evidence review.
Thank you, this report is not an extensive evidence review. |
Mary Steele Williams |
Association for Molecular Pathology |
|
Thank you for the opportunity to submit comments on the Technology Assessment
(TA), "Update on Horizon Scans of Genetic Tests Currently Available for Clinical
Use in Cancers."
The Association for Molecular Pathology (AMP) is an international medical
and professional association representing approximately 1,800 physicians,
doctoral scientists, and medical technologists who perform laboratory testing
based on knowledge derived from molecular biology, genetics and genomics. Membership
includes professionals who work within academic medicine, government, and
the in vitro diagnostics industry.
First, the term "genetic test" and its definition are used both too liberally
as well as sometimes incorrectly in the document. The document includes
and summarizes numerous tests that are not typically considered genetic or
even molecularly based, i.e., not dependent upon the analysis of DNA or RNA. If
AHRQ wishes these tests to remain in the document and for the document to
remain factually correct, AMP strongly encourages the authors to rename the
TA a scan of laboratory tests, or at least genomic tests, and not strictly
genetic tests. As for genetic testing, this list is incomplete. An
example is testing for mutations in the PMS2 gene associated with non-polyposis
colorectal cancer (Lynch syndrome), which was first offered in 2008. Additionally,
the definition of genetic test included on page 9 of the TA is erroneously
cited as being from the Secretary's Advisory Committee on Genetics, Health
and Society 2008 report on US System of Oversight of Genetic Testing. However,
the definition in the TA is actually the definition from the Secretary's
Advisory Committee on Genetic Testing report on Enhancing the Oversight of
Genetic Tests issued in 2000. AMP requests that the authors modify
the TA to use the more recent definition of genetic tests.
It is important for the value of the document that a distinction be made
between genomic tests that assess inherited genetic mutations, acquired somatic
mutations, and pharmacogenomics (tests for common genetic variation involved
with therapeutic drug response)). Additionally, AMP recommends that
predictive genetic testing be distinguished from diagnostic testing. All
of these distinctions will help to ensure that the report is viewed as a
credible and useful tool by private and public payers and other policy makers.
AMP has previously submitted comments and sent letters to federal agencies
on the nomenclature used to describe molecular tests. Whenever possible,
AMP encourages the authors to describe tests based on their molecular entities
rather than their brand names since numerous labs might offer the same or
similar test under a different name. By listing tests using their brand
names, some may read this as a de facto endorsement of one test over another
by the agency, something AMP suspects AHRQ does not intend.
The authors may be aware that stakeholders and federal regulators are currently
engaged in discussions on the appropriate oversight of laboratory-developed
tests (LDTs). In contrast to in vitro diagnostic test kits, most LDTs
are developed and validated for use in a single laboratory and currently
not subject to FDA approval or clearance. Developers of LDTs do not
consider themselves to be manufacturers as they do not manufacture or produce
products, i.e., test kits, for sale. AMP requests that the TA be
modified to distinguish between test manufacturers and clinical laboratories
offering LDTs to ordering physicians.
While AMP respects the specific expertise represented by the authors from
the Tufts Medical Center Evidence-based Practice Center, the absence of genetics
and molecular-based medical expertise in this report is of great concern. Inclusion
of subject matter experts as authors (or at least as editors) would not only
help ensure that the document is a comprehensive survey of currently available
tests, but also would fulfill the most rudimentary requirements of such a
survey, e.g., differentiating genetic from non-genetic tests. AMP respectfully
requests that the authors include subject matter experts prior to the finalization
of this report to improve its accuracy and completeness. AMP stands
ready to offer assistance to AHRQ on this report and future reports on molecular
diagnostics.
Thank you very much for the opportunity to comment on this draft TA and
we hope these comments improve the document, enhance its utility and assist
AHRQ in putting out the highest quality educational instrument. AMP offers
its assistance as AHRQ moves forward on this and other technology assessments. |
We are aware that some professional societies vary in their interpretation
of a "genetic test" and our description as defined by the
SACGHS uses a broad definition of a "genetic test".
This definition has been used by our previous reports. The current report utilizes
the updated definition and we have edited for the most recent citation.
The main objective of this report is not identify which are LDT based or
manufacturer based, but to have a horizon scanning of new genomic tests that
fit into the pre-defined eligibility criteria.
Thank you for your interest in participating in future TAs.
We will definitely use your expertise during the process of conducting
a full systematic review. |
1. Names are alphabetized by last name.
Those who did not disclose name are labeled "Anonymous Reviewer 1," "Anonymous
Reviewer 2," etc.
2. Affiliation is labeled "NA" for
those who did not disclose affiliation.
3. If listed, page number, line number, or
section refers to the draft report.
4. If listed, page number, line number, or
section refers to the final report.
Return to Contents
Current as of August 2011
Internet Citation:
Update of Horizon Scans of Genetic Tests Currently Available for
Clinical Use in Cancers: Disposition of Comments.
August 2011. Rockville, MD: Agency for Healthcare Research and Quality.
http://www.ahrq.gov/clinic/ta/comments/horizongentests/
|